


BMS-794833

Cat. No.:	HY-10497												
CAS No.:	1174046-72-0												
Molecular Formula:	C ₂₃ H ₁₅ ClF ₂ N ₄ O ₃												
Molecular Weight:	468.84												
Target:	c-Met/HGFR; VEGFR												
Pathway:	Protein Tyrosine Kinase/RTK												
Storage:	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>2 years</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 year</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	2 years		-20°C	1 year
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	2 years											
	-20°C	1 year											



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (213.29 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.1329 mL	10.6646 mL	21.3292 mL
	5 mM	0.4266 mL	2.1329 mL	4.2658 mL
	10 mM	0.2133 mL	1.0665 mL	2.1329 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (5.33 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (5.33 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

BMS-794833 is a VEGFR2 and Met inhibitor extracted from patent WO2009094417, compound example 1; has IC₅₀s of 15 and 1.7 nM, respectively.

IC₅₀ & Target

VEGFR2	Met
15 nM (IC ₅₀)	1.7 nM (IC ₅₀)

In Vitro

BMS794833 inhibits Met receptor activated gastric carcinoma cell line, GTL-16, with an IC₅₀ of 39 nM^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BMS-794833 is active by greater than 50% tumor growth inhibition for at least one tumor doubling time in the GTL-16 gastric carcinoma model. No toxicity is observed at any of the dose levels when administered once daily for a duration of 14 days^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]

GTL-16 cells are inoculated in to 96 well microtiter plates in 0.5% fetal calf serum and incubated at 37°C, 5% CO₂, 95% air and 100% relative humidity for 24 h prior to addition of a compound. Cells are treated with BMS-794833 for an additional 72 h. Growth inhibition is calculated^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. WO2009094417

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA